R&D Spending Showdown: Ascendis Pharma A/S vs Corcept Therapeutics Incorporated

Ascendis vs Corcept: A Decade of R&D Investment

__timestampAscendis Pharma A/SCorcept Therapeutics Incorporated
Wednesday, January 1, 20141969800018372000
Thursday, January 1, 20154052800015419000
Friday, January 1, 20166602200023844000
Sunday, January 1, 20179958900040376000
Monday, January 1, 201814028100075247000
Tuesday, January 1, 201919162100089017000
Wednesday, January 1, 2020260904000114764000
Friday, January 1, 2021295867000113864000
Saturday, January 1, 2022379624000130991000
Sunday, January 1, 2023413454000184353000
Monday, January 1, 2024307004000
Loading chart...

Igniting the spark of knowledge

R&D Spending Trends: A Decade of Innovation

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Ascendis Pharma A/S and Corcept Therapeutics Incorporated have shown distinct trajectories in their R&D investments. Ascendis Pharma A/S has consistently increased its R&D spending, growing from approximately $20 million in 2014 to over $410 million in 2023, marking a staggering 1,965% increase. In contrast, Corcept Therapeutics Incorporated, while also increasing its R&D budget, has shown a more modest growth of around 900%, from $18 million in 2014 to $184 million in 2023. This divergence highlights Ascendis Pharma's aggressive push towards innovation, potentially positioning it as a leader in the pharmaceutical industry. As these companies continue to invest in R&D, the future of drug development looks promising, with new breakthroughs on the horizon.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025